Valuation: Interpace Biosciences, Inc.

Market Cap 2.85Cr 2.54Cr 2.35Cr 2.14Cr 4.04Cr 270.87Cr 4.1Cr 28Cr 11Cr 141.35Cr 11Cr 10Cr 450.61Cr P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 2.72Cr 2.42Cr 2.24Cr 2.04Cr 3.85Cr 258.33Cr 3.91Cr 27Cr 11Cr 134.8Cr 10Cr 10Cr 429.74Cr EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 day-2.28%
1 week-14.17%
Current month-19.41%
1 month-20.16%
3 months-32.46%
6 months-51.76%
Current year-16.27%
1 week 5.05
Extreme 5.05
6.13
1 month 5.05
Extreme 5.05
6.55
Current year 5.05
Extreme 5.05
12
1 year 4.03
Extreme 4.0275
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
48.5
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2020
Director of Finance/CFO 34 21/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 21/06/2016
Director/Board Member 73 01/01/2016
Director/Board Member 64 22/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Free

Director

69,252 0.2501%
20/08/26 Exercice

Chief Financial Officer

13,85,045 5.0015%
20/08/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%-14.17%+10.74%+14.44% 2.85Cr
-0.24%+7.20%+11.92%+28.26% 12TCr
-2.06%+1.72%+7.67%+88.07% 9.93TCr
-2.80%-1.81%+116.54%+825.74% 5.67TCr
+2.78%+6.42%-5.38%+78.37% 2.86TCr
-1.74%+1.74%+24.00%+90.61% 2.59TCr
-2.19%+1.86%+11.19%+56.66% 2.58TCr
-2.86%+1.32%+33.62%+373.09% 2.15TCr
-0.27%-2.93%-19.97%-3.65% 2.08TCr
-0.65%-6.95%+4.36%+84.85% 1.83TCr
Average -1.23%+0.72%+19.47%+163.65% 4.15TCr
Weighted average by Cap. -1.19%+2.40%+23.92%+179.43%

Financials

2024 2025
Net sales 4.69Cr 4.17Cr 3.87Cr 3.52Cr 6.64Cr 445.36Cr 6.74Cr 46Cr 18Cr 232.41Cr 18Cr 17Cr 740.88Cr 3.87Cr 3.44Cr 3.19Cr 2.9Cr 5.48Cr 367.56Cr 5.57Cr 38Cr 15Cr 191.81Cr 15Cr 14Cr 611.45Cr
Net income 67.02L 59.57L 55.22L 50.24L 94.8L 64Cr 96.32L 6.64Cr 2.6Cr 33Cr 2.52Cr 2.46Cr 105.81Cr 2.46Cr 2.18Cr 2.02Cr 1.84Cr 3.48Cr 233.23Cr 3.53Cr 24Cr 9.54Cr 121.71Cr 9.22Cr 9.03Cr 388Cr
Net Debt 43.95L 39.07L 36.21L 32.94L 62.17L 42Cr 63.16L 4.35Cr 1.71Cr 22Cr 1.65Cr 1.61Cr 69Cr -13.22L -11.75L -10.89L -10L -18.7L -13Cr -19L -1.31Cr -51.33L -6.55Cr -49.61L -48.56L -21Cr
Projected Income Statement - Annual - Interpace Biosciences, Inc.
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
16/26/16 $5.150 -2.28% 1,752
15/26/15 $5.270 -4.49% 3,267
14/26/14 $5.518 -6.47% 261
13/26/13 $5.900 -3.75% 3,747
12/26/12 $6.130 +2.17% 6,338

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Interpace Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. IDXG Stock